European results in neutron therapy of malignant salivary gland tumors.
Standard
European results in neutron therapy of malignant salivary gland tumors. / Krüll, Andreas; Schwarz, R; Engenhart, R; Huber, P; Lessel, A; Koppe, H; Favre, A; Breteau, N; Auberger, T.
in: Bull Cancer Radiother, Jahrgang 83 Suppl, 1996.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - European results in neutron therapy of malignant salivary gland tumors.
AU - Krüll, Andreas
AU - Schwarz, R
AU - Engenhart, R
AU - Huber, P
AU - Lessel, A
AU - Koppe, H
AU - Favre, A
AU - Breteau, N
AU - Auberger, T
PY - 1996
Y1 - 1996
N2 - In Europe to date, 501 patients with salivary gland tumors have been treated with neutrons alone or with combined modalities. The most common histological types are adenoid cystic carcinomas, mucoepidermoid carcinomas and malignant mixed tumors. The results of conventional radiotherapy are suboptimal in inoperable or incompletely resected salivary gland tumors and in recurrent disease. The pooled data of some international series for low linear energy transfer radiation show a local control of 28%. Especially in advanced tumors neutron therapy can improve local control and should be the treatment of choice. The clinical data from different therapy centers in Europe show local control of 67% in gross disease.
AB - In Europe to date, 501 patients with salivary gland tumors have been treated with neutrons alone or with combined modalities. The most common histological types are adenoid cystic carcinomas, mucoepidermoid carcinomas and malignant mixed tumors. The results of conventional radiotherapy are suboptimal in inoperable or incompletely resected salivary gland tumors and in recurrent disease. The pooled data of some international series for low linear energy transfer radiation show a local control of 28%. Especially in advanced tumors neutron therapy can improve local control and should be the treatment of choice. The clinical data from different therapy centers in Europe show local control of 67% in gross disease.
KW - Humans
KW - Europe
KW - Prognosis
KW - Survival Analysis
KW - Follow-Up Studies
KW - Combined Modality Therapy
KW - Radiotherapy Dosage
KW - Neoplasm Staging
KW - Radiotherapy, High-Energy/methods
KW - Carcinoma, Adenoid Cystic/mortality/pathology/radiotherapy
KW - Carcinoma, Mucoepidermoid/mortality/pathology/radiotherapy
KW - Fast Neutrons
KW - Salivary Gland Neoplasms/mortality/pathology/radiotherapy
KW - Humans
KW - Europe
KW - Prognosis
KW - Survival Analysis
KW - Follow-Up Studies
KW - Combined Modality Therapy
KW - Radiotherapy Dosage
KW - Neoplasm Staging
KW - Radiotherapy, High-Energy/methods
KW - Carcinoma, Adenoid Cystic/mortality/pathology/radiotherapy
KW - Carcinoma, Mucoepidermoid/mortality/pathology/radiotherapy
KW - Fast Neutrons
KW - Salivary Gland Neoplasms/mortality/pathology/radiotherapy
M3 - SCORING: Journal article
VL - 83 Suppl
ER -